Biotinylated SARS-CoV-2 Spike S1 Domain

Product Description

Biotinylated SARS-CoV-2 Spike S1 Domain
Catalog number: B2010508
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 25 ug
Molecular Weight or Concentration: 76 kDa
Supplied as: Lyophilized Powder
Applications: molecular component of many serological and antigenic assays for SARS-CoV-2
Storage: -20℃
Keywords: Spike S1, S1 protein, Biotin S1
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

Download SARS-CoV-2 Brochure

References:
1: Kadam SB, Sukhramani GS, Bishnoi P, Pable AA, Barvkar VT. SARS-CoV-2, the
pandemic coronavirus: Molecular and structural insights. J Basic Microbiol. 2021
Mar;61(3):180-202.

2: Kemp SA, Collier DA, Datir R, Ferreira I, Gayed S, Jahun A, Hosmillo M, Rees-
Spear C, Mlcochova P, Lumb IU, Roberts DJ, Chandra A, Temperton N; CITIID-NIHR
BioResource COVID-19 Collaboration; COVID-19 Genomics UK (COG-UK) Consortium,
Sharrocks K, Blane E, Briggs J, van GM, Smith K, Bradley JR, Smith C, Doffinger
R, Ceron-Gutierrez L, Barcenas-Morales G, Pollock DD, Goldstein RA, Smielewska
A, Skittrall JP, Gouliouris T, Goodfellow IG, Gkrania-Klotsas E, Illingworth C,
McCoy LE, Gupta RK. Neutralising antibodies in Spike mediated SARS-CoV-2
adaptation. medRxiv [Preprint]. 2020 Dec 29:2020.12.05.20241927.

3: Shajahan A, Supekar NT, Gleinich AS, Azadi P. Deducing the N- and
O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2.
Glycobiology. 2020 Dec 9;30(12):981-988.

4: Zhang L, Jackson CB, Mou H, Ojha A, Peng H, Quinlan BD, Rangarajan ES, Pan A,
Vanderheiden A, Suthar MS, Li W, Izard T, Rader C, Farzan M, Choe H. SARS-CoV-2
spike-protein D614G mutation increases virion spike density and infectivity. Nat
Commun. 2020 Nov 26;11(1):6013.

5: Zhou H, Chen X, Hu T, Li J, Song H, Liu Y, Wang P, Liu D, Yang J, Holmes EC,
Hughes AC, Bi Y, Shi W. A Novel Bat Coronavirus Closely Related to SARS-CoV-2
Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein.
Curr Biol. 2020 Jun 8;30(11):2196-2203.e3. doi: 10.1016/j.cub.2020.05.023. Epub
2020 May 11. Erratum in: Curr Biol. 2020 Oct 5;30(19):3896.

6: Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of
SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19.
Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149.

7: Kaur G, Lungarella G, Rahman I. SARS-CoV-2 COVID-19 susceptibility and lung
inflammatory storm by smoking and vaping. J Inflamm (Lond). 2020 Jun 10;17:21.

8: Bangaru S, Ozorowski G, Turner HL, Antanasijevic A, Huang D, Wang X, Torres
JL, Diedrich JK, Tian JH, Portnoff AD, Patel N, Massare MJ, Yates JR 3rd,
Nemazee D, Paulson JC, Glenn G, Smith G, Ward AB. Structural analysis of full-
length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science.
2020 Nov 27;370(6520):1089-1094.

9: Wang Y, Wang L, Cao H, Liu C. SARS-CoV-2 S1 is superior to the RBD as a
COVID-19 subunit vaccine antigen. J Med Virol. 2021 Feb;93(2):892-898.
10: Ho M. Perspectives on the development of neutralizing antibodies against
SARS-CoV-2. Antib Ther. 2020 Apr;3(2):109-114.

Products Related to Biotinylated SARS-CoV-2 Spike S1 Domain : SARS-CoV-2